Deflazacort Paving its Way in the Treatment of Oral Lesions- Review and A Case Report
Simran Verma*, Bhakti Soman Patil and Deepa Das
Department of Oral Medicine and Maxillofacial Radiology, Dr. G. D. Pols
Foundation's YMT Dental College and Hospital, India
*Corresponding Author: Simran Verma; Department of Oral Medicine and
Maxillofacial Radiology, Dr. G. D. Pols Foundation's YMT Dental College and Hospital,
Received: September 15, 2022; Published: October 06, 2022
Deflazacort is a synthetic corticosteroid characterized by its favorable pharmacokinetic profile, distinct pharmacodynamic properties
and a good safety profile when compared to other corticosteroids. Few of the substantial potential properties of this drug include
lack of sodium- retaining activity, strong anti- inflammatory/immunosuppressive activity, and lower interference with carbohydrate
metabolism and phosphocalcium metabolism in comparison with older corticosteroids. They have always formed an important component
of dermatological therapy, but recently has gained importance to be used as a therapeutic drug to treat various oral mucosal
lesions. Here, we also reported a case of erosive lichen planus in a 40-year-old man who was treated with deflazacort. He was managed
with tapering systemic doses of deflazacort, following which there was complete remission of the lesions.
Keywords: Deflazacort; Adverse Effects; Oral Lichen Planus; Immunosuppressants; Autoimmune; Glucose Metabolism
- Nayak S and Acharjya B. “Deflazacort versus other glucocorticoids: a comparison”. Indian Journal of Dermatology 4 (2008): 167-170.
- “Deflazacort UKDI New Medicines on the Market” (1998).
- Luca Parente. “Deflazacort: therapeutic index, relative potency, and equivalent doses versus other corticosteroids”. Parente BMC Pharmacology and Toxicology 18 (2017): 1.
- Piccoli A., et al. “Bioequivalence of deflazacort and prednisone in the treatment of idiopathic nephrotic syndrome, a pilot study”. Current Therapeutic Research 54 (1993): 588-597.
- Scudeletti M., et al. “Effect of single oral doses of prednisone and deflazacort on human lymphocyte distribution and functions: Analysis with monoclonal antibodies”. Advances in Experimental Medicine and Biology 171 (1984): 335-344.
- Gonzalez-Castaneda RE., et al. “Deflazacort induced stronger immunosuppression than expected”. Clinical Rheumatology 26 (2007): 935-940.
- Montecucco C., et al. “Serum osteocalcin (bone Gla protein) following corticosteroid therapy in postmenopausal women with rheumatoid arthritis. Comparison of the effect of prednisone and deflazacort”. Clinical Rheumatology 7 (1988): 366-371.
- Pagano G., et al. “Acute effect of prednisone and deflazacort on glucose tolerance in prediabetic subjects”. European Journal of Clinical Pharmacology 22 (1982): 469-471.
- Lippuner K., et al. “Effects of deflazacort versus prednisone on bone mass, body composition, and lipid profile: a randomized, double blind study in kidney transplant patients”. The Journal of Clinical Endocrinology and Metabolism 83 (1998): 3795-3802.
- , et al. “Deflazacort: A Glucocorticoid with Few Metabolic Adverse Effects but Important Immunosuppressive Activity”. Advances in Therapy 24.5 (2007): 1052-1060.
- Ferraris JR., et al. “Effect of deflazacort versus methylprednisone on growth, body composition, lipid profile, and bone mass after renal transplantation. The Deflazacort Study Group”. Pediatric Nephrology 14 (2000): 682-688.
- Gupta J., et al. “Vitamin D in the treatment of oral lichen planus: A pilot clinical study”. Journal of Indian Academy of Oral Medicine and Radiology 31 (2019): 222-227.
- Aina Torrejon-Moya. “Oral Lichen Planus and Dental Implants: Protocol and Systematic Review”. Journal of Clinical Medicine 9 (2020): 4127.
- , et al. “Oral pemphigus: long term behavior and clinical response to treatment with deflazacort in sixteen case”. Journal of Oral Pathology and Medicine 29 (2000): 145-152.
- C Scully and M Mignogna. British Journal of Oral and Maxillofacial Surgery 46 (2008): 272-277.
- Elis Penteado Arantes., et al. “Melkersson Rosenthal Syndrome Complicated with Facial Hemiespasm and Intracranial Hypertension”. Novel Techniques in Nutrition and Food Science 2 (2020): 000609.
- Konagala RK., et al. “Effect of pretreatment medication on postendodontic pain: A double-blind, placebo-controlled study”. Journal of Conservative Dentistry 1 (2019): 54-58.
- Seixas R., et al. “Herpes Zoster Infection in an Immunocompromised Patient: A Case Report and Review of Corticosteroid’s Role”. Cureus1 (2022): e20908.
- Loftus J., et al. “Randomized, double-blind trial of deflazacort vs. prednisone in juvenile chronic or rheumatoid arthritis: A relatively bone sparing effect of deflazacort”. Pediatrics 88 (1991): 428-436.
- , et al. “Toxic epidermal necrolysis associated with deflazacort therapy with nephrotic syndrome”. Kidney Research and Clinical Practice 33 (2014): 222-225.